Health Professional Radio - Podcast

Returning guest, Dr. Eric Klein, Chairman of the Glickman Urological and Kidney Institute at Cleveland Clinic discusses new 20-year outcomes from a development study of the Oncotype DX Genomic Prostate Score® (GPS) test that was recently published in JCO Precision Oncology (March 2021).  The study highlights the role of the GPS test, the only genomic test for prostate cancer with 20-year outcomes, in assessing the risk of long-term distant metastases (DM) and prostate cancer-specific mortality (PCSM) for patients with localized prostate cancer. Eric A. Klein, MD, is the Chairman of the Glickman Urological & Kidney Institute and a staff member in the Taussig Cancer Institute at Cleveland Clinic. His clinical interests are cancers of the prostate,  testis, and kidney.  For several years, including the current edition, Dr. Klein is listed in Best Doctors in America. Board-certified in urology, Dr. Klein is a frequent lecturer and visiting professor at numerous national and international univer